Influenza Vaccine Safety and Effectiveness in Healthcare Providers
Monitoring Seasonal and Pandemic Vaccine Safety and Effectiveness in Healthcare Providers:A Prospective Cohort Study
Visão geral do estudo
Status
Condições
Descrição detalhada
Participants in Year 1 (2009/10) will be recruited beginning Oct. 1 through the end of the pandemic H1N1 influenza immunization campaign.
Participants will be followed from the day of vaccination until the end of the influenza season approximately Oct-April for each season.
At the initial visit, participants will have 1 tube of blood (10cc) collected at the time of enrolment to determine baseline antibody titres against pandemic H1N1 and the influenza strains in the past and current year's seasonal influenza vaccines.
Participants will receive automated email reminders with links to follow-up web-based questionnaires at weekly intervals following the completion of the baseline survey and until the end of the influenza season.
If a participant reports a respiratory illness, they will receive a follow-up questionnaire asking details of the illness including the occurrence of respiratory illness and associated symptoms, contact with patients or household members that had respiratory illness, respiratory symptom-related healthcare utilization, prescription or over-the-counter products used for treatment of the respiratory illness, and number of days of work missed due to respiratory illness or worked with symptomatic respiratory tract infection. An email will be sent to each participant every Monday morning during the season reminding the participant to complete their weekly diary and report and send in their nasal swab if they have symptoms of an acute respiratory illness.
At the initial visit participants will be taught how to collect their nasal swab and will practice doing their own swab in the presence of the study nurse/research associate. Participants will be instructed to collect a nasal swab and return the swabs as soon as possible after onset of ILI or respiratory illness (target < 48h after onset). Participants will be asked to collect the swab if they develop symptoms compatible with a viral respiratory tract infection (fever without an apparent source OR new symptoms with at least 2 of the following -cough, runny/stuffy nose, sneezing, sore/scratchy throat, hoarseness, malaise, myalgia, headache, fatigue OR one local symptom (runny/stuffy nose, sneezing, sore/scratchy throat, hoarseness, cough) plus one systemic symptom (fever, malaise, myalgia, headache, fatigue). If they prefer, a nasopharyngeal swab will be collected by a member of the study team as soon as possible after the onset of symptoms.
Tipo de estudo
Inscrição (Real)
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
1)18-69 years old, inclusive, as of Sept. 1 on the year of enrolment; 2)understand the study, agree to its provisions, and give written informed consent to participate; 3)available for follow-up for at least 1 influenza season 4)have convenient access to a computer with internet access and basic skills for use of the internet; 5)employed full-or part -time (> 8 hours/week) in an acute care hospital (in any occupation) or, if a physician or midwife, working at least 8 hours per week in an acute care hospital.
Exclusion Criteria:
- planning to spend more than two consecutive weeks outside of Canada during the winter study period (Oct. 15- Apr. 15);
- received an immunoglobulin within 6 months of study entry;
- planning to take leave from work for more than two consecutive weeks during the winter study period (e.g. maternity or medical leave);
- participating in a trial that would result in receipt of an investigational medication during the study period
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Assessment of the safety and tolerability of seasonal and pandemic influenza vaccine among a cohort of HCP
Prazo: October to April each year
|
Health care providers will receive automated email reminders with a link to report any changes in their health within 4 weeks of vaccination.
|
October to April each year
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To validate published ILI case definitions in a cohort of HCP
Prazo: October to April each year
|
A cohort of HCP will be asked via an automated email to report the presence of an upper respiratory illness and to self collect a nasal swab to be tested for influenza.
|
October to April each year
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Shelly A McNeil, MD, Dalhousie University
- Investigador principal: Allison McGeer, MD, Mount Sinai Hospital
- Investigador principal: Anne McCarthy, MD, The Ottawa Hospital
- Investigador principal: Mark Loeb, MD, Hamilton Health Sciences Center
- Investigador principal: Grant Stiver, MD, Vancouver General Hospital
- Investigador principal: Brenda Coleman, MD, Mount Sinai Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 114142
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .